

training, or to Ms. Daubert's participation in or eligibility for any Federal program relating to student loans, education grants, or educational assistance of any type or kind, for which she would otherwise be qualified to receive or be considered to receive (educational assistance), unless that educational assistance involves research or research training.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Lyle W. Bivens,

Director, Office of Research Integrity.

[FR Doc. 96-6026 Filed 3-13-96; 8:45 am]

BILLING CODE 4160-17-P

Agency for Health Care Policy and Research

Health Care Policy and Research Emphasis Panel; Notice of Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of March 1996:

Name: Health Care Policy and Research Special Emphasis Panel

Date and Time: March 26, 1996, 1:30 p.m.

Place: Agency for Health Care Policy and Research, 2101 E. Jefferson Street, Suite 400, Rockville, MD 20852.

Open March 26, 1996, 1:30 p.m. to 1:45 p.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with conducting review of grant applications for Conference Support.

Agenda: The open session of the meeting on March 26 from 1:30 p.m. to 1:45 p.m. will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing grant applications for Conference Support. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Linda Blankenbaker, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594-1438.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: March 7, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96-6072 Filed 3-13-96; 8:45 am]

BILLING CODE 4160-90-M

Centers for Disease Control and Prevention

Advisory Committee for Injury Prevention and Control (ACIPC) and the ACIPC Family and Intimate Violence Prevention Subcommittee Meetings: Change of Location

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 61 FR 7110—dated February 26, 1996.

SUMMARY: Notice is given that the meeting location for the Advisory Committee for Injury Prevention and Control (ACIPC) and the ACIPC Family and Intimate Violence Prevention Subcommittee of the Centers for Disease Control and Prevention (CDC) has changed. The meeting times, dates, status, purpose, and matters to be discussed announced in the original notice remain unchanged.

ORIGINAL LOCATION: Wyndham Garden Hotel-Atlanta Buckhead, 3340 Peachtree Road, NE, Atlanta, Georgia 30326.

NEW LOCATION: Crowne Plaze Ravinia, 4355 Ashford-Dunwoody Road, Atlanta, Georgia 30346.

CONTACT PERSON FOR MORE INFORMATION: Mr. Thomas A. Bartenfeld, Acting Executive Secretary, ACIPC, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway, NE, M/S K02, Atlanta, Georgia 30341-3724, telephone 770/488-4230.

Dated: March 8, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-6068 Filed 3-13-96; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 96N-0085]

Drug Export; ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that American Cyanamid Co., Lederle-Praxis Biologicals Div. has filed an application requesting approval for the

export of the human biological product ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed to the Federal Republic of Germany.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM-610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that American Cyanamid Co., Lederle-Praxis Biologicals Div., 401 North Middletown Rd., Pearl River, NY 10965, has filed an application requesting approval for the export of the human biological product ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed to the Federal Republic of Germany. The ACEL-IMUNE® Diphtheria-Tetanus Toxoid (Acellular) Pertussis Vaccine Adsorbed is for immunization against diphtheria, tetanus and pertussis (whooping cough) from 15 months to 6 years of age. The application was received and filed in the Center for Biologics Evaluation and Research on February 23, 1996, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch